GT Biopharma, Inc.GTBPNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank21
Year-over-Year Change
Year-over-year operating income growth rate
Percentile
P21
Within normal range
vs 3Y Ago
-3.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | -65.43% |
| Q3 2025 | -123.53% |
| Q2 2025 | 21.69% |
| Q1 2025 | 48.66% |
| Q4 2024 | -4.41% |
| Q3 2024 | 7.73% |
| Q2 2024 | -26.37% |
| Q1 2024 | 2.43% |
| Q4 2023 | -1.47% |
| Q3 2023 | 13.78% |
| Q2 2023 | 1.20% |
| Q1 2023 | 36.57% |
| Q4 2022 | 17.73% |
| Q3 2022 | -133.01% |
| Q2 2022 | 44.62% |
| Q1 2022 | 70.06% |
| Q4 2021 | -205.31% |
| Q3 2021 | -35.91% |
| Q2 2021 | 84.89% |
| Q1 2021 | -1223.69% |
| Q4 2020 | -12.65% |
| Q3 2020 | -24.84% |
| Q2 2020 | -45.61% |
| Q1 2020 | -23.56% |
| Q4 2019 | 90.22% |
| Q3 2019 | -288.55% |
| Q2 2019 | 43.81% |
| Q1 2019 | -31.18% |
| Q4 2018 | 98.68% |
| Q3 2018 | -4450.32% |
| Q2 2018 | 27.97% |
| Q1 2018 | -21.54% |
| Q4 2017 | 95.36% |
| Q3 2017 | -9772.06% |
| Q2 2017 | 16.45% |
| Q1 2017 | -87.10% |
| Q4 2016 | 67.51% |
| Q3 2016 | -19.28% |
| Q2 2016 | 45.63% |
| Q1 2016 | -34.15% |